BIIB
Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 202.36$. Average daily volumn in 3 months 1.14M. Market cap 31.58B
Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD Lastest price : 215.65$. Total volume : 14.61k. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Biogen Inc. (BIIB)
Last Price
215.65$Change
-0.33Volume
14.61k
| Previous Close | 215.98 |
| Open | 213.11 |
| Day Range | 215.40-215.90 |
| Bid | 215.10 x 800 |
| Ask | 220.80 x 900 |
| Volume | 14.61k |
| Average Volume | 1.14M |
| Market Cap | 31.58B |
| Beta | 0.42 |
| 52 Week Range | 187.16-372.12 |
| Trailing P/E | 21.87 |
| Foward P/E | 13.48 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | N/A |
Financial Details
Organization
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Market Cap:
31.58BRevenue:
10.98BTotal Assets:
23.88BTotal Cash:
2.26B
News about "Biogen Inc."
Biogen Inc. stock outperforms competitors on strong trading day
Source from : MarketWatch - 23 hours ago
Shares of Biogen Inc. advanced 1.60% to $215.98 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P ...See details»
The Petri Dish: FDA to fast-track Biogen's next Alzheimer's drug
Source from : The Business Journals - 11 hours ago
The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory ...See details»
Biogen’s Alzheimer’s drug will get priority review in US
Source from : The Boston Globe - 1 days ago
The Food and Drug Administration accepted the application under the accelerated approval pathway and is expected to complete the review by Jan. 6, the companies said in a statement.See details»
FDA decision on Eisai, Biogen Alzheimer's drug due in January
Source from : Reuters - 1 days ago
The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's and Biogen Inc's experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on ...See details»
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Wedbush Securities Inc.
Source from : Defense World - 2 days ago
Wedbush Securities Inc. lowered its position in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 27.5% during the first quarter, Holdings Channel reports. The fund owned 1,832 shares of the ...See details»
Xponance Inc. Acquires 364 Shares of Biogen Inc. (NASDAQ:BIIB)
Source from : Defense World - 4 days ago
Xponance Inc. grew its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 3.9% in the first quarter, HoldingsChannel reports. The fund owned 9,791 shares of the biotechnology company’s stock after ...See details»
Can Biogen’s backup plan for Alzheimer’s succeed?
Source from : The Boston Globe on MSN.com - 3 days ago
Biogen and its partner Eisai have submitted another Alzheimer’s therapy to the FDA. But just as before, experts are divided on the drug.See details»
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Source from : Business Insider - 7 days ago
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.See details»
Biogen to reimburse employees who travel 100-plus miles for abortion
Source from : The Business Journals - 8 days ago
In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access ...See details»
Ritholtz Wealth Management Sells 233 Shares of Biogen Inc. (NASDAQ:BIIB)
Source from : ETF Daily News - 7 days ago
Ritholtz Wealth Management lowered its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The ...See details»
Biogen stops clinical trial tracking Aduhelm
Source from : MarketWatch on MSN.com - 13 days ago
Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company ...See details»
IBM Retirement Fund Trims Stock Position in Biogen Inc. (NASDAQ:BIIB)
Source from : ETF Daily News - 10 days ago
IBM Retirement Fund lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 5.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the ...See details»
Biogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority review
Source from : Seeking Alpha - 1 days ago
The U.S. Food and Drug Administration (FDA) granted priority review to Biogen (BIIB) and Eisai's (ESALY) (ESALF) lecanemab to treat mild cognitive impairment ((MCI)) due ...See details»
Pharmalittle: Some scientists want more Vertex CRISPR data; Biogen Alzheimer’s drug to get priority review
Source from : STAT - 1 days ago
The FDA will expedite its review of Biogen's and Eisai's experimental Alzheimer's drug lecanemab, with a decision due by Jan. 6, 2023, the companies said.See details»